<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 19, 2026 at 10:40 pm by All in One SEO v5.0.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://helixgatebiotechreview.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Helixgate</title>
		<link><![CDATA[https://helixgatebiotechreview.com]]></link>
		<description><![CDATA[Helixgate]]></description>
		<lastBuildDate><![CDATA[Thu, 19 Nov 2026 19:45:56 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://helixgatebiotechreview.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/?utm_campaign=rss]]></link>
			<title>STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 19:45:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/19/hims-noom-enter-peptide-market-mainstream-products-health-risks/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/19/hims-noom-enter-peptide-market-mainstream-products-health-risks/?utm_campaign=rss]]></link>
			<title>STAT+: Peptide market poised to explode with new Hims and Noom launches</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 19:45:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/19/merck-isomorphic-labs-partner-to-develop-oncology-drug-candidates/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/19/merck-isomorphic-labs-partner-to-develop-oncology-drug-candidates/?utm_campaign=rss]]></link>
			<title>STAT+: Merck, Isomorphic Labs partner to develop oncology drug candidates</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 19:45:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/pfizer-starna-in-vivo-cell-therapy-autoimmune-disease-deal/875018/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/pfizer-starna-in-vivo-cell-therapy-autoimmune-disease-deal/875018/]]></link>
			<title>Pfizer leaps into ‘in vivo’ CAR-T with latest China deal</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 19:05:35 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/white-house-withdraw-heidi-overton-fda-commissioner-nomination/874961/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/white-house-withdraw-heidi-overton-fda-commissioner-nomination/874961/]]></link>
			<title>White House pulls nomination for FDA nominee Overton</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 19:05:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/regeneron-fda-approve-cemdisiran-livsayis-myasthenia-gravis-alnylam/875160/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/regeneron-fda-approve-cemdisiran-livsayis-myasthenia-gravis-alnylam/875160/]]></link>
			<title>With FDA nod, Regeneron brings an RNAi drug to autoimmune disease</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 19:05:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/us-china-biotech-report-commission-supply-chain-2026/875170/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/us-china-biotech-report-commission-supply-chain-2026/875170/]]></link>
			<title>China could ‘corner’ biopharma sector with new plan, US panel warns</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 19:05:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/sanofi-fda-infilbray-venglustat-approve-gaucher/875167/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/sanofi-fda-infilbray-venglustat-approve-gaucher/875167/]]></link>
			<title>Sanofi gains FDA clearance for Gaucher disease pill</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 19:05:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/in-chinas-shadow-pfizer-ceo-calls-for-ai-savings-to-bolster-big-pharma]]></guid>
			<link><![CDATA[https://www.biospace.com/business/in-chinas-shadow-pfizer-ceo-calls-for-ai-savings-to-bolster-big-pharma]]></link>
			<title>In China’s shadow, Pfizer CEO calls for AI savings to bolster Big Pharma</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:14:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/pfizer-launches-into-autoimmune-car-t-with-chinas-starna-in-up-to-2-6b-deal]]></guid>
			<link><![CDATA[https://www.biospace.com/business/pfizer-launches-into-autoimmune-car-t-with-chinas-starna-in-up-to-2-6b-deal]]></link>
			<title>Pfizer launches into autoimmune CAR T with China&#8217;s Starna in up to $2.6B deal</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:13:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/merck-scraps-centerpiece-of-2-7b-arqule-buy-after-late-stage-safety-concerns]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/merck-scraps-centerpiece-of-2-7b-arqule-buy-after-late-stage-safety-concerns]]></link>
			<title>Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:13:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/ctad-2026-biogen-aribio-lead-the-way-in-slowing-cognitive-decline-in-alzheimers]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/ctad-2026-biogen-aribio-lead-the-way-in-slowing-cognitive-decline-in-alzheimers]]></link>
			<title>CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:13:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/CTAD-2026-bms-cobenfy-eases-alzheimer&apos;s-psychosis-as-expected-but-safety-events-raise-questions]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/CTAD-2026-bms-cobenfy-eases-alzheimer&apos;s-psychosis-as-expected-but-safety-events-raise-questions]]></link>
			<title>CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:13:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/job-trends/ramping-up-3-biotechs-growing-their-workforce-after-series-c-raises]]></guid>
			<link><![CDATA[https://www.biospace.com/job-trends/ramping-up-3-biotechs-growing-their-workforce-after-series-c-raises]]></link>
			<title>Ramping up: 3 biotechs growing their workforce after series C raises</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:13:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/job-trends/9-biotechs-will-cut-at-least-half-their-california-workforces]]></guid>
			<link><![CDATA[https://www.biospace.com/job-trends/9-biotechs-will-cut-at-least-half-their-california-workforces]]></link>
			<title>9 biotechs will cut at least half their California workforces</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:13:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/abbvie-grooves-with-discos-solid-tumor-tech-in-up-to-2-5b-licensing-deal]]></guid>
			<link><![CDATA[https://www.biospace.com/business/abbvie-grooves-with-discos-solid-tumor-tech-in-up-to-2-5b-licensing-deal]]></link>
			<title>AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:13:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/the-untapped-potential-of-drug-repurposing]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/the-untapped-potential-of-drug-repurposing]]></link>
			<title>The untapped potential of drug repurposing</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:13:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/sanofi-secures-first-fda-approval-to-treat-neurological-symptoms-in-rare-metabolic-disease]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/sanofi-secures-first-fda-approval-to-treat-neurological-symptoms-in-rare-metabolic-disease]]></link>
			<title>Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:13:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/regeneron-racks-up-another-first-as-fda-greenlights-generalized-myasthenia-gravis-rna-drug]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/regeneron-racks-up-another-first-as-fda-greenlights-generalized-myasthenia-gravis-rna-drug]]></link>
			<title>Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:13:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/actinogens-sole-drug-fails-pivotal-alzheimers-study-sinking-stock-80]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/actinogens-sole-drug-fails-pivotal-alzheimers-study-sinking-stock-80]]></link>
			<title>Actinogen’s sole drug fails pivotal Alzheimer’s study, sinking stock 80%</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:13:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/novartis-projects-slowed-growth-pins-hopes-on-billions-in-pipeline-potential]]></guid>
			<link><![CDATA[https://www.biospace.com/business/novartis-projects-slowed-growth-pins-hopes-on-billions-in-pipeline-potential]]></link>
			<title>Novartis projects slowed growth, pins hopes on billions in pipeline potential</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 18:12:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/bioprocessing/growing-apart-culture-based-sterility-test-alternatives/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/bioprocessing/growing-apart-culture-based-sterility-test-alternatives/]]></link>
			<title>Growing Apart: Culture-Based Sterility Test Alternatives</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 16:09:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/bioprocessing/one-record-from-factory-floor-to-patient/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/bioprocessing/one-record-from-factory-floor-to-patient/]]></link>
			<title>One Record, From Factory Floor to Patient</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 16:09:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/bioprocessing/tuning-extracellular-vesicle-production-and-analytics-for-compliance/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/bioprocessing/tuning-extracellular-vesicle-production-and-analytics-for-compliance/]]></link>
			<title>Tuning Extracellular Vesicle Production and Analytics for Compliance</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 16:09:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/bioprocessing/the-advent-of-automated-gene-engineered-til-manufacturing/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/bioprocessing/the-advent-of-automated-gene-engineered-til-manufacturing/]]></link>
			<title>The Advent of Automated, Gene-Engineered TIL Manufacturing</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 16:09:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/artificial-intelligence/london-calling-flagship-expands-in-u-k-to-build-ai-native-platform-companies/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/artificial-intelligence/london-calling-flagship-expands-in-u-k-to-build-ai-native-platform-companies/]]></link>
			<title>London Calling: Flagship Expands in U.K. to Build AI-Native Platform Companies</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 16:09:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/cancer/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to-immunotherapy-in-mice/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/cancer/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to-immunotherapy-in-mice/]]></link>
			<title>Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 16:09:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/translational-medicine/crispr-screening-reveals-how-genetic-variants-drive-neurodegenerative-risk/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/translational-medicine/crispr-screening-reveals-how-genetic-variants-drive-neurodegenerative-risk/]]></link>
			<title>CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 16:09:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/biospace-layoff-tracker]]></guid>
			<link><![CDATA[https://www.biospace.com/biospace-layoff-tracker]]></link>
			<title>nChroma halves workforce, BioXcel lets execs go</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 15:21:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://phys.org/news/2026-11-cellular-recycling-gene-yields-hard.html]]></guid>
			<link><![CDATA[https://phys.org/news/2026-11-cellular-recycling-gene-yields-hard.html]]></link>
			<title>Switching off cellular recycling gene increases yields of hard-to-make drug target proteins</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 10:36:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.labiotech.eu/partner/cns-drug-discovery-ai-eeg/]]></guid>
			<link><![CDATA[https://www.labiotech.eu/partner/cns-drug-discovery-ai-eeg/]]></link>
			<title>CNS drug discovery: How AI-powered EEG profiling can sharpen go/no-go decisions</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 09:34:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.labiotech.eu/in-depth/chinese-biotech-competition-european-biotech/]]></guid>
			<link><![CDATA[https://www.labiotech.eu/in-depth/chinese-biotech-competition-european-biotech/]]></link>
			<title>Chinese biotech competition and the payer squeeze are reshaping European biotech</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 09:34:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/fda-approves-livsayis-cemdisiran-generalized-myasthenia-gravis-6943.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/fda-approves-livsayis-cemdisiran-generalized-myasthenia-gravis-6943.html]]></link>
			<title>FDA Approves Livsayis (cemdisiran) for the Treatment of Generalized Myasthenia Gravis</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 09:03:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/fda-approves-lembaz-adrabetadex-improve-survival-infantile-onset-niemann-pick-type-c-6941.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/fda-approves-lembaz-adrabetadex-improve-survival-infantile-onset-niemann-pick-type-c-6941.html]]></link>
			<title>FDA Approves Lembaz (adrabetadex) to Improve Survival in Infantile-Onset Niemann-Pick Disease, Type C</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 09:03:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/fda-approves-infilbray-venglustat-neurological-manifestations-type-3-gaucher-6942.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/fda-approves-infilbray-venglustat-neurological-manifestations-type-3-gaucher-6942.html]]></link>
			<title>FDA Approves Infilbray (venglustat) to Treat Neurological Manifestations of Type 3 Gaucher Disease</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 09:03:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/novo-presents-preclinical-human-data-suggesting-role-amylin-calcitonin-receptor-activation-22690.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/novo-presents-preclinical-human-data-suggesting-role-amylin-calcitonin-receptor-activation-22690.html]]></link>
			<title>Novo Presents Preclinical and Human Data Suggesting a Role for Amylin and Calcitonin Receptor Activation in Preserving Bone During Weight Loss</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/cardiff-oncology-receives-fda-fast-track-designation-onvansertib-first-line-ras-mutated-metastatic-22692.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/cardiff-oncology-receives-fda-fast-track-designation-onvansertib-first-line-ras-mutated-metastatic-22692.html]]></link>
			<title>Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/uniquity-bio-announces-statistically-significant-clinically-meaningful-positive-topline-phase-2-22695.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/uniquity-bio-announces-statistically-significant-clinically-meaningful-positive-topline-phase-2-22695.html]]></link>
			<title>Uniquity Bio Announces Statistically Significant and Clinically Meaningful Positive Topline Phase 2 Results for Solrikitug in Eosinophilic Esophagitis</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/biogen-s-diranersen-demonstrates-increasing-clinical-benefit-two-years-early-alzheimer-s-22694.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/biogen-s-diranersen-demonstrates-increasing-clinical-benefit-two-years-early-alzheimer-s-22694.html]]></link>
			<title>Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/merck-announces-update-bellwave-clinical-development-program-evaluating-nemtabrutinib-22689.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/merck-announces-update-bellwave-clinical-development-program-evaluating-nemtabrutinib-22689.html]]></link>
			<title>Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/laboratoires-pierre-fabre-announce-fda-fast-track-designation-elticertinib-nsclc-22691.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/laboratoires-pierre-fabre-announce-fda-fast-track-designation-elticertinib-nsclc-22691.html]]></link>
			<title>Laboratoires Pierre Fabre Announce FDA Fast Track Designation for Elticertinib in NSCLC</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/bristol-myers-squibb-presents-first-clinical-data-two-phase-3-studies-adept-program-evaluating-22693.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/bristol-myers-squibb-presents-first-clinical-data-two-phase-3-studies-adept-program-evaluating-22693.html]]></link>
			<title>Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss]]></link>
			<title>STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 03:56:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/18/biotech-news-fda-discloses-reasons-for-rejecting-summit-drug/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/18/biotech-news-fda-discloses-reasons-for-rejecting-summit-drug/?utm_campaign=rss]]></link>
			<title>STAT+: FDA discloses reasons for rejecting Summit drug</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 03:56:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/18/fda-after-heidi-overton-burning-questions-agency-future/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/18/fda-after-heidi-overton-burning-questions-agency-future/?utm_campaign=rss]]></link>
			<title>STAT+: 7 burning questions about the FDA’s post-Overton future</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 03:56:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.nature.com/articles/s41587-026-03405-9]]></guid>
			<link><![CDATA[https://www.nature.com/articles/s41587-026-03405-9]]></link>
			<title>Author Correction: The global patent landscape of bispecific antibodies: technological innovations and therapeutic applications</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 03:14:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/summits-rejection-letter-reveals-fdas-deeper-concerns-about-trial-design-safety]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/summits-rejection-letter-reveals-fdas-deeper-concerns-about-trial-design-safety]]></link>
			<title>Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 02:33:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/gsk-nabs-fda-greenlight-for-second-lung-cancer-asset-from-nuvalent-buy]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/gsk-nabs-fda-greenlight-for-second-lung-cancer-asset-from-nuvalent-buy]]></link>
			<title>GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 02:33:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/government-actions-are-hitting-smaller-biotechs-the-hardest-report]]></guid>
			<link><![CDATA[https://www.biospace.com/business/government-actions-are-hitting-smaller-biotechs-the-hardest-report]]></link>
			<title>Government actions are hitting smaller biotechs the hardest: Report</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 02:33:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://helixgatebiotechreview.com/]]></guid>
			<link><![CDATA[https://helixgatebiotechreview.com/]]></link>
			<title>Home</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 03:39:54 +0000]]></pubDate>
		</item>
				</channel>
</rss>
